Mediastinal isolated myeloid sarcoma: a single-institution experience

D’Angiò, Mariella; Paesano, Paolo; Quattrocchi, Luisa; Barberi, Walter; Ceglie, Teresa; Avagnina, Irene; Propris, Maria Stefania De; Trisolini, Silvia Maria; Testi, Anna Maria

doi:10.3109/10428194.2014.914201

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven of the patients with negative scans had later scans which documented continued absence of tumor at 7 months to 5 years . Of the other 17 cases with negative PET/CT scans, one died after transplant and 16 relapsed within 13 months: 10 in extramedullary sites , 4 in marrow , and 2 in both extramedullary sites and marrow .…”

Section: Resultsmentioning

confidence: 99%

“…Negative scans were achieved in 38. Of the 35 with available follow‐up, 18 continued disease‐free at 3 months to 6 years (10 over 1 year) . Seven of the patients with negative scans had later scans which documented continued absence of tumor at 7 months to 5 years .…”

Section: Resultsmentioning

confidence: 99%

“…Among 18 AML patients given transplants after induction therapies, 4 died of complications and 14 obtained clinical responses, documented on PET/CT in 6 . Nine patients continued well, three at 5, 5, and 6 years after auto transplants and five at 3 to 24 months after allogeneic grafts . One other remained PET/CT‐positive after transplant but after salvage radiation was well at 2 years .…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

¹⁸FDG‐PET/CT: 21st century approach to leukemic tumors in 124 cases

Cunningham

Kohno

2016

American J Hematol

View full text Add to dashboard Cite

Extramedullary tumors remain an obstacle to curing more acute leukemia patients. Their incidence is unknown because the presence of occult tumors that contribute to relapse is not routinely sought as in other cancers. No standard approach exists for treating tumors at most sites, apparent clinical response is typically followed by further tumors, and achievement of lengthy remission is uncommon. Body scanning with 18 FDG PET/CT now provides a means to identify the extent of occult tumors that enables directed tumor eradication and a way to evaluate tumor response. To evaluate its potential benefits, analysis was undertaken of 124 published cases scanned after apparent tumors were diagnosed. Clinical and radiologic exams underestimated extent of disease in over half of 100 cases. Among 70 cases that reported scans after various treatments, 70% achieved negative scans. Half relapsed subsequently but disease-free survivals up to 6 years were documented. These reported cases add to our knowledge of extramedullary leukemia in showing that further tumors are more likely than marrow relapse, clinical and radiologic evaluation of response is inadequate, intensive chemotherapy alone generally does not prevent progression and is associated with significant mortality, and tumor-directed plus systemic therapies appears the most effective approach, particularly to AML tumors. This analysis suggests this technology could increase our ability to eradicate all foci of leukemia, and identify tumors responsible for refractory, residual, and relapsed disease.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%